Kaempferol regulates OPN-CD44 pathway to inhibit the atherogenesis of apolipoprotein E deficient mice

Toxicology and Applied Pharmacology

Volumn 257, Issue 3, 2011, Pages 405-411

  Xiao, Hong Bo ^a   Lu, Xiang Yang ^a   Sun, Zhi Liang ^a   Zhang, Heng Bo ^b  

^a HUNAN AGRICULTURAL UNIVERSITY   (China)

^b Furong District Red Cross Hospital   (China)

Author keywords

Apolipoprotein e deficient mouse; Cluster of differentiation 44; Inflammation; Kaempferol; Osteopontin

Indexed keywords

APOLIPOPROTEIN E; CYTOKINE; KAEMPFEROL; OSTEOPONTIN; PROTEIN CLUSTER OF DIFFERENTIATION 44; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; HERMES ANTIGEN; KAEMPFEROL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; C57BL 6 MOUSE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VASODILATATION; ANIMAL; AORTA; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; VASCULAR ENDOTHELIUM;

MUS;

ANIMALS; ANTIGENS, CD44; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; KAEMPFEROLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPONTIN; REACTIVE OXYGEN SPECIES; VASODILATION;

EID: 84855739117     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.09.024     Document Type: Article

References (40)

1. Calderón-Montaño J.M., Burgos-Morón E., Pérez-Guerrero C., López-Lázaro M. A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem. 2011, 211:298-344.
2. Chen J., Kuhlencordt P., Urano F., Ichinose H., Astern J., Huang P.L. Effects of chronic treatment with l-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:97-103.
3. Chiba S., Okamoto H., Kon S., Kimura C., Murakami M., Inobe M., Matsui Y., Sugawara T., Shimizu T., Uede T., Kitabatake A. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 2002, 16:111-117.
4. Cuff C.A., Kothapalli D., Azonobi I., Chun S., Zhang Y., Belkin R., Yeh C., Secreto A., Assoian R.K., Rader D.J., Pure E. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J. Clin. Invest. 2001, 108:1031-1040.
5. Gavrila D., Li W.G., McCormick M.L., Thomas M., Daugherty A., Cassis L.A. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1671-1677.
6. Isoda K., Kamezawa Y., Ayaori M., Kusuhara M., Tada N., Ohsuzu F. Osteopontin mRNA is expressed by smooth muscle derived foamy cells in human atherosclerotic lesions of the aorta. J. Clin. Invest. 1993, 92:2814-2820.
7. Isoda K., Kamezawa Y., Ayaori M., Kusuhara M., Tada N., Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003, 107:679-681.
8. Kauser K., da Cunha V., Fitch R., Mallari C., Rubanyi G.M. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:1679-1685.
9. Kim J.D., Liu L., Guo W., Meydani M. Chemical structure of flavonols in relation to modulation of angiogenesis and immune-endothelial cell adhesion. J. Nutr. Biochem. 2006, 17:165-176.
10. Kitamura M., Iwabuchi K., Kitaichi N., Kon S., Kitamei H., Namba K., Yoshida K., Denhardt D.T., Rittling S.R., Ohno S., Uede T., Onoé K. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J. Immunol. 2007, 178:6567-6572.
11. Kolodgie F.D., Burke A.P., Farb A., Weber D.K., Kutys R., Wight T.N., Virmani R. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1642-1648.
12. Krettek A., Sjöberg S. CD44 - a new cardiovascular drug target or merely an innocent bystander?. Cardiovasc. Hematol. Disord. Drug Targets 2009, 9:293-302.
13. Krettek A., Sukhova G.K., Schönbeck U., Libby P. Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: possible role for a feedback loop in endothelial cells. Am. J. Pathol. 2004, 165:1571-1581.
14. Levesque H., Girard N., Maingonnat C., Delpech A., Chauzy C., Tayot J., Courtois H., Delpech B. Localization and solubilization of hyaluronan and of the hyaluronan-binding protein hyaluronectin in human normal and arteriosclerotic arterial walls. Atherosclerosis 1994, 105:51-62.
15. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
16. Lin Y.H., Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J. Biol. Chem. 2001, 276:46024-46030.
17. Lotito S.B., Frei B. Dietary flavonoids attenuate tumor necrosis factor alpha-induced adhesion molecule expression in human aortic endothelial cells. Structure-function relationships and activity after first pass metabolism. J. Biol. Chem. 2006, 281:7102-7110.
18. Ma Y., Malbon C.C., Williams D.L., Thorngate F.E. Altered gene expression in early atherosclerosis is blocked by low level apolipoprotein E. PLoS One 2008, 3:e2503.
19. Marsh L.M., Cakarova L., Kwapiszewska G., von Wulffen W., Herold S., Seeger W. Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L442-L452.
20. Matsui Y., Rittling S.R., Okamoto H., Inobe M., Jia N., Shimizu T., Akino M., Sugawara T., Morimoto J., Kimura C., Kon S., Denhardt D., Kitabatake A., Uede T. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1029-1034.
21. Mo S.F., Zhou F., Lv Y.Z., Hu Q.H., Zhang D.M., Kong L.D. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol. Pharm. Bull. 2007, 30:1551-1556.
22. Ng T.B., Liu F., Lu Y., Cheng C.H., Wang Z. Antioxidant activity of compounds from the medicinal herb Aster tataricus. Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 2003, 136:109-115.
23. Okamoto H. Osteopontin and cardiovascular system. Mol. Cell. Biochem. 2007, 300:1-7.
24. Osman H.E., Maalej N., Shanmuganayagam D., Folts J.D. Grape juice but not orange or grapefruit juice inhibits platelet activity in dogs and monkeys. J. Nutr. 1998, 128:2307-2312.
25. Papakonstantinou E., Roth M., Block L.H., Mirtsou-Fidani V., Argiriadis P., Karakiulakis G. The differential distribution of hyaluronic acid in the layers of human atheromatic aortas is associated with vascular smooth muscle cell proliferation and migration. Atherosclerosis 1998, 138:79-89.
26. Raza K., Thambyrajah J., Townend J.N. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lesson for atherosclerotic disease?. Circulation 2000, 102:1470-1472.
27. Sahai A., Malladi P., Melin-Aldana H., Green R.M., Whitington P.F., et al. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:264-273.
28. Shanahan C.M., Weissberg P.L., Metcalfe J.C. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ. Res. 1993, 73:193-204.
29. Singh M., Ananthula S., Milhorn D.M., Krishnaswamy G., Singh K. Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front. Biosci. 2007, 12:214-221.
30. Setsukinai K., Urano Y., Kakinuma K., Majima H.J., Nagano T. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J. Biol. Chem. 2003, 278:3170-3175.
31. Stenvinkel P. Endothelial dysfunction and inflammation-is there a link?. Nephrol. Dial. Transplant. 2001, 16:1968-1971.
32. Toole B.P., Wight T.N., Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. J. Biol. Chem. 2002, 277:4593-4596.
33. Trepels T., Zeiher A.M., Fichtlscherer S. The endothelium and inflammation. Endothelium 2006, 13:423-429.
34. Tu Y.C., Lian T.W., Yen J.H., Chen Z.T., Wu M.J. Antiatherogenic effects of kaempferol and rhamnocitrin. J. Agric. Food Chem. 2007, 55:9969-9976.
35. Vetrone S.A., Montecino-Rodriguez E., Kudryashova E., Kramerova I., Hoffman E.P., Liu S.D., Miceli M.C., Spencer M.J. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J. Clin. Invest. 2009, 119:1583-1594.
36. Wu K.K., Wu T.J., Chin J., Mitnaul L.J., Hernandez M., Cai T.Q., Ren N., Waters M.G., Wright S.D., Cheng K. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 2005, 181:251-259.
37. Xiao H.B., Jun-Fang, Lu X.Y., Chen X.J., Chao-Tan, Sun Z.L. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level. Eur. J. Pharmacol. 2009, 616:213-222.
38. Xie Z., Pimental D.R., Lohan S., Vasertriger A., Pligavko C., Colucci W.S., Singh K. Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J. Cell. Physiol. 2001, 188:132-138.
39. Zern T.L., West K.L., Fernandez M.L. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J. Nutr. 2003, 133:2268-2272.
40. Zhao L., Hall J.A., Levenkova N., Lee E., Middleton M.K., Zukas A.M., Rader D.J., Rux J.J., Pure E. CD44 regulates vascular gene expression in a proatherogenic environment. Arterioscler. Thromb. Vasc. Biol. 2007, 27:886-892.